Total Visits

Views
Functional ...190

Total Visits Per Month

June 2025July 2025August 2025September 2025October 2025November 2025December 2025
Functional ...813448156

File Visits

Views
functional_mapping_akt_signaling_biomarkers_response_fairlane_trial_neoadjuvant_ipatasertib_plus_paclitaxel_triple_negative_breast_cancer_2022.pdf84
functional_mapping_akt_signaling_biomarkers_response_fairlane_trial_neoadjuvant_ipatasertib_plus_paclitaxel_triple_negative_breast_cancer_2022_figura10.pdf27
functional_mapping_akt_signaling_biomarkers_response_fairlane_trial_neoadjuvant_ipatasertib_plus_paclitaxel_triple_negative_breast_cancer_2022_figura2.pdf25
functional_mapping_akt_signaling_biomarkers_response_fairlane_trial_neoadjuvant_ipatasertib_plus_paclitaxel_triple_negative_breast_cancer_2022_figura4.pdf24
functional_mapping_akt_signaling_biomarkers_response_fairlane_trial_neoadjuvant_ipatasertib_plus_paclitaxel_triple_negative_breast_cancer_2022_figura9.pdf23
functional_mapping_akt_signaling_biomarkers_response_fairlane_trial_neoadjuvant_ipatasertib_plus_paclitaxel_triple_negative_breast_cancer_2022_figura7.pdf22
functional_mapping_akt_signaling_biomarkers_response_fairlane_trial_neoadjuvant_ipatasertib_plus_paclitaxel_triple_negative_breast_cancer_2022_figura1.pdf20
functional_mapping_akt_signaling_biomarkers_response_fairlane_trial_neoadjuvant_ipatasertib_plus_paclitaxel_triple_negative_breast_cancer_2022_figura5.pdf20
functional_mapping_akt_signaling_biomarkers_response_fairlane_trial_neoadjuvant_ipatasertib_plus_paclitaxel_triple_negative_breast_cancer_2022_figura6.pdf19
functional_mapping_akt_signaling_biomarkers_response_fairlane_trial_neoadjuvant_ipatasertib_plus_paclitaxel_triple_negative_breast_cancer_2022_figura3.pdf17

Top country views

Views
Ireland54
United States46
Brazil16
Singapore16
Germany9
Spain9
China8
Canada3
United Kingdom3
India3

Top cities views

Views
Dublin50
Singapore15
Boydton8
Ashburn6
Barcelona5
Nuremberg4
The Dalles3
Almont2
Chicago2
Muscat2